Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck CancerGlobeNewsWire • 03/16/21
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 StudyGlobeNewsWire • 01/07/21
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway InhibitorGlobeNewsWire • 12/29/20
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First DaySeeking Alpha • 12/13/20
Immutep shares soar 190% on positive results in trial of breast cancer treatmentMarket Watch • 12/10/20
Immutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer StudyGlobeNewsWire • 12/09/20
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast CancerGlobeNewsWire • 12/09/20
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical DevelopmentGlobeNewsWire • 11/18/20
Immutep's TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual MeetingGlobeNewsWire • 11/02/20
Immutep to Collaborate with LabCorp to Develop Oncology Services and ProductsGlobeNewsWire • 10/29/20
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 PatientsGlobeNewsWire • 10/23/20
Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020GlobeNewsWire • 10/19/20